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Background and Study Aims. Endoscopic placement of self-expanding metal stents (SEMSs) is indicated for palliation of inoperable
malignant biliary obstruction. A fully covered biliary SEMS (WallFlex Biliary RX Boston Scientific, Natick, USA) was assessed
for palliation of extrahepatic malignant biliary obstruction. Patients and Methods. 58 patients were included in this prospective,
multicenter series conducted under an FDA-approved IDE. Main outcome measurements included (1) absence of stent occlusion
within six months or until death, whichever occurred first and (2) technical success, need for reintervention, bilirubin levels, stent
patency, time to stent occlusion, and adverse events. Results. Technical success was achieved in 98% (57/58), with demonstrated
acute removability in two patients. Adequate clinical palliation until completion of followup was achieved in 98% (54/55) of
evaluable patients, with 1 reintervention due to stent obstruction after 142 days. Mean total bilirubin decreased from 8.9mg/dL to
1.2mg/dL at 1 month. Device-related adverse events were limited and included 2 cases of cholecystitis. One stentmigrated following
radiation therapy.Conclusions.TheWallFlex Biliary fully covered stent yielded technically successful placementwith uncomplicated
acute removal where required, appropriate reduction in bilirubin levels, and low rates of stent migration and occlusion.This SEMS
allows successful palliation of malignant extrahepatic biliary obstruction.
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1. Introduction
Endoscopic stent placement is now a standard therapy for
management of most biliary strictures [1–3]. Plastic stents are
generally employed in patients with benign or indeterminate
strictures and formalignant strictures in patients with limited
life expectancy [4]. Self-expanding metal stents (SEMSs) are
indicated in patients with confirmed inoperable malignant
biliary strictures. Bare SEMS are typically employed at the
porta hepatis, while bare, partially covered, or fully covered
SEMSmay be used for extrahepatic lesions. Bare and partially
covered SEMSs are prone to late occlusion due to ingrowth
through the struts of the stent or overgrowth at the ends by
tumor or hyperplastic tissue [5]. Somedesigns of partially and
fully covered SEMS may be more prone to migration [6]. A
fully covered stent with design features that limit migration
yet facilitate repositioning or removal would provide optimal
palliation of malignant strictures without significant risk
related to inaccurate placement, size selection, or ultimate
tissue diagnosis. TheWallFlex Biliary RX Fully covered Stent
is designed to meet these needs. This study was undertaken
to evaluate the safety and clinical effectiveness of this new
stent for palliative treatment in patients with inoperable
extrahepatic malignant biliary obstruction.
2. Patients/Materials and Methods
Thismultisite, single arm, prospective studywas performed at
10 centers under an Investigational Device Exemption (IDE)
from the Food and Drug Administration (FDA). The study
protocol and amendments were approved by Institutional
Review Boards at all participating centers. All patients, or
their legal representatives, provided written Informed Con-
sent prior to enrollment. An Independent Medical Reviewer
assessed events of stent occlusion or migration and all
events resulting in death. This expert endoscopist was not
an employee of the sponsor or involved with a participating
center.
Inclusion criteria required (1) presence of inoperable
malignant nonhilar extrahepatic biliary obstruction, (2) clin-
ical symptoms of biliary obstruction, (3) age 18 or older, and
(4) Willingness and ability to comply with study procedures
and provide signed informed consent. Exclusion criteria
included any of the following: (1) participation in another
investigational study within 90 days prior to consent, (2)
Strictures that could not be traversed by the delivery system,
(3) perforation of any ductwithin the biliary tree, (4) presence
of a biliary SEMS, (5) presence of any esophageal or duodenal
stent, (6) contraindications to endoscopy, (7) sensitivity to
any components of the stent or delivery system, (8) Active
hepatitis, (9) intrahepatic metastases that extensively involve
both lobes of the liver, and (10) life expectancy of <3 months.
The primary endpoint was adequate clinical palliation
of biliary obstruction, as demonstrated by maintenance of
bilirubin below 3mg/dL or reduction by >30% if the baseline
value was greater than 3mg/dL and absence of evidence of
stent occlusion until death or 6 months of followup, which-
ever occurred first. A stent was considered occluded if the
patient presented with elevation of total bilirubin that the
treating physician deemed to be due to recurrent biliary
obstruction and endoscopic imaging evidence of obstruction.
Secondary endpoints included (1) ability to deploy the
stent in satisfactory position, (2) ability to successfully repo-
sition or remove the stent, if required, at initial placement or
at stent failure, without clinically significant complications or
technical difficulties, (3) occurrence and severity of device
and procedure-related adverse events, (4) need for reinter-
vention, (5) reduction in symptoms of biliary obstruction
(jaundice, pruritus, right upper quadrant pain, fever, nausea,
vomiting, and dark urine) at all visits, (6) patency at 1, 3, and
6 months, and (7) time to stent occlusion.
2.1. Follow-Up Visits. Stent patency at 1 month was assessed
by total bilirubin level and at 1, 3, and 6 months by lack of
obstructive symptoms. Follow-up visits were primarily con-
ducted by phone, with inperson unscheduled visits required
in case of recurrent obstructive symptoms.
2.2. Enrollment and Analysis Cohorts. A total of 74 patients
who signed the informed consent form (ICF) were con-
sidered enrolled. After enrollment, fourteen patients failed
screening relative to eligibility criteria and were withdrawn
from the study without study treatment. Two patients were
successfully treated with the study device but later found not
to have met eligibility criteria. Per protocol, these patients
were not part of the intent-to-treat (ITT) cohort, defined as
those patients who signed the ICF, met eligibility criteria, and
had the stent placement procedure initiated. The ITT cohort
of 58 patients was used for assessment of baseline information
and safety. Per protocol, assessment of the primary endpoint
and secondary effectiveness endpoints was performed on the
evaluable cohort, defined as ITT patients with at least one
week of followup. Three patients were excluded from the
evaluable cohort on the basis of death unrelated to the device
prior to 1 week of followup (2) or failed placement of the study
device at the index procedure with conversion to another
device (1). Hence, the evaluable cohort had 55 patients.
2.3. Stent Design. TheWallflex Biliary RX fully covered stent
is a radiopaque SEMSmade of braided nitinol with a translu-
cent silicone polymer (Permalume) lining of its entire length
to prevent tumor or hyperplastic tissue ingrowth, whilemain-
taining friction between stent wires and bile duct wall. The
stent ends are flared to minimize risk of migration. Looped
wires at the ends aim to minimize the risk of impaling or
ulcerating the mucosa. The stent has a retrieval loop at the
distal end to facilitate removal or repositioning in the event
of misplacement or migration.The flared ends collapse when
subjected to a withdrawal force.The stent is available in 8 and
10mm diameters of varying lengths (8mm × 60 and 80mm,
10mm × 40, 60, and 80mm).
The delivery system is a coaxial tube design. The outer
sheath constrains the stent before deployment and can be
advanced to reconstrain the stent, if repositioning is necessa-
ry, after partial deployment down to the marked reconstrain-
ment limit (approx. 80% of the stent length).
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2.4. Statistics. A literature review conducted prior to the
study noted that the majority (∼80%) of publications on
covered biliary SEMS report stent occlusion rates of 25%
or less. Therefore, for this study, 55 evaluable patients were
required to test whether the stent occlusion rate at 6 months
or death was significantly less than 25%, using a 1-sided
binomial test with a significance level of 5% and a power of
90% for an expected stent occlusion rate of 10%.
Kaplan-Meier analysis was used to determine the rates
of survival and stent occlusion based on available followup
information, with censoring for discontinued and deceased
patients and beyond six months after stent placement. The
number of biliary obstructive symptoms at each followupwas
summarized by the mean and its 95% confidence interval,
based on the normal distribution. A paired t-test was used
to test the significance of reduction in the mean number of
symptoms from baseline to 6 months, using the subset of
patients with paired data available. Effectiveness measures
were summarized by success rates and exact Clopper-Pearson
95% confidence intervals.
3. Results
The ITT cohort included 30 men and 28 women, with a
mean age of 68.9 years (range 23–89.8). The top five reported
biliary obstructive symptoms were jaundice (82.8%), dark
urine (37.9%), right upper quadrant (RUQ)pain (34.5%), pru-
ritus (32.8%), and nausea (17.2%). Tumor type and stricture
location are summarized in Tables 1 and 2. Twenty patients
(34.5%) had a previous biliary sphincterotomy.
3.1. Stent Placement and Removal. Stent placement (Figure 1)
was technically successful in 57 of 58 patients (98%) in the
ITT cohort (Table 3). Deployment was attempted but failed
in 1 patient due to severe angulation of the duodenoscope.
In this patient the deployment system was removed and a
noninvestigational biliary SEMS was placed during the index
procedure.
Three stents were deployed but immediately removed
from two patients to better match the pathologic anatomy.
In one, a stent that was deemed to be of excessive length
was deployed, but subsequently removed and replaced with
a shorter sent. In the other patient, a 10mm × 60mm stent
proved insufficiently long and a 10mm × 40mm stent placed
through the initially placed stent did not expand completely
within the tight stricture. Both were removed without tech-
nical or clinical complications, after which a 10mm × 80mm
stent was placed in good position. Thus, three stents were
successfully removed without adverse events (Table 3). No
patients underwent attempted stent removal after the initial
stent placement procedure. All 57 ultimately placed study
stents were 10mm in diameter, with lengths of 40mm in 14%,
60mm in 72%, and 80mm in 14% of stents.
3.2. Effectiveness. A summary of key effectiveness results is
provided in Table 3. Overall 54 of 55 evaluable patients (98%)
had adequate clinical palliation of biliary obstruction until
death or completion of followup. This rate of stent occlusion
(2%) was significantly less than those commonly noted in the
Table 1: Types of malignancy at baseline.
Cancer type ITT subjects(𝑁 = 58 subjects)
Pancreatic 45 (77.6%)
Cholangiocarcinoma 3 (5.2%)
Ampullary 2 (3.4%)
Colon 2 (3.4%)
Lung 2 (3.4%)
Other undefined malignancy
Retroperitoneal mass, suspect sarcoma
Malignant adenopathy of the porta hepatic
portacaval, and pericardial regions 4 (6.9%)
Peripancreatic malignant lymphadenopathy
Lymphoma to porta hepatis
Table 2: Baseline stricture locations.
Location of stricture Baseline
𝑁 = 58 (%)
Distal common bile duct (CBD) 41 (70.7 %)
Mid CBD 9 (15.5%)
Proximal common bile duct 5 (8.6%)
Distal CBD and mid CBD 1 (1.7%)
Junction of distal CBD and mid CBD 1 (1.7%)
Papilla 1 (1.7%)
literature (25%) (𝑃 < 0.0001). Of the 55 patients, 23 were
followed to 6 months, 25 died while on study, and 7 were
discontinued prior tomonth 6 or death. One patient with dis-
continued followup presented with bacteremia, cholangitis,
and fever due to stent occlusion 142 days after stent place-
ment. In this case, the distal end of the stent was collapsed
on itself at the level of the papilla with repositioning wire
tines extending from the papilla which detached during stent
manipulation.The distal end of the stent was balloon dilated,
and a commercial uncovered SEMS was placed inside the
occluded stent with prompt clinical improvement. Another
patient had an ampullary cancer and adequate clinical palli-
ation, but experienced asymptomatic stent migration at day
84, which was deemed a result of response to radiation ther-
apy. The patient did not require restenting. Five additional
patients were dropped from followup for reasons unrelated
to the stent at 33, 45, 50, 138, and 161 days after placement,
including 3 patients that underwent Whipple procedures
despite not originally being considered surgical candidates,
1 patient categorized as lost to followup on day 138 despite
multiple contact attempts after the week 1 visit when no
biliary obstructive symptoms were reported, and 1 patient
who withdrew consent early due to failing health.
Total bilirubin levels at baseline and month 1 were
available for 45 of the 55 evaluable patients. Among them,
44/45 (97.8%) demonstrated successful maintenance of total
bilirubin by the previously mentioned criteria, with the mean
level reducing from 8.9mg/dL (range 0.4–27.1) to 1.2mg/dL
(0.2–8.0).One patientwith underlying hepatitis C and known
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Figure 1: (a)–(c) Cholangiographic images of malignant biliary stricture and WallFlex Biliary Stent placement. (a) 254 × 254mm (96 ×
96DPI), (b) 338 × 338mm (72 × 72DPI), and (c) 338 × 338mm (72 × 72DPI).
Table 3: Key effectiveness results.
Measure
Measure of
success
𝑁 (%)
[95% CI]
Primary endpoint
Adequacy of palliation 54 (98.2%) [90.3%, 100%]∗
Secondary endpoints
Stent deployment/technical
success 57 (98.3%) [90.8%, 100%]
Number of biliary obstructive
symptoms at baseline
Mean ± SD (𝑁) 2.7 ± 1.76 [2.0, 3.50]
Range (Min, Max) (1, 8)
Median 2
Number of biliary obstructive
symptoms at month 6
Mean ± SD (𝑁) 0.1 ± 0.46 [0.00, 0.33]
Range (Min,Max) (0, 2)
Median 0
Stent patency 21 (91.3%) [72.0%, 98.9%]
Reduction of bilirubin level at
month 1 44 (97.8%) [88.2%, 99.9%]
∗Intent-to-treat (58).
cirrhosis failed to demonstrate successful reduction in total
bilirubin at the month 1 visit (baseline total bilirubin =
11.0mg/dL; month 1 = 8.0mg/dL). In ten patients month 1
total bilirubin levels were not obtained due to early death
(3) missing blood draw (3), early discontinuation (2), patient
refusal (1), and loss to followup (1).
The mean number of reported biliary obstructive symp-
toms was reduced at each visit compared to the prior visit,
ranging from a baseline mean for all 55 evaluable patients of
2.73±1.60 (standard deviation (SD)) (range 1–8, median 2) to
0.13±0.46 (SD) reported symptoms (range 0–2, median 0) at
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Figure 2: Kaplan-Meier curve of patient survival and freedom from
stent occlusion 81 × 40mm (300 × 300DPI).
the month 6 visit. Analyzing the subset of 23 subjects with
paired data available, there was a significant reduction in
the mean number of symptoms from baseline to 6 months
(𝑃 < 0.0001). By protocol criteria, stent patency was evident
in 91.3% at Month 6.
The estimated patient survival rate and the estimated
rate of freedom from stent occlusion, as a function of time
after stent placement, are both demonstrated in KaplanMeier
curves in Figure 2. One patient (1.8%) experienced a stent
occlusion. Kaplan-Meier analysis based on the 55 evaluable
patients yielded an estimated stent occlusion rate at 6 months
of 3.7% (SD 3.6%). The median time to stent occlusion is
at least 210 days. Hence, the study stent appears effective in
providing biliary obstruction-free palliation to most patients
until death or at least 6 months after stenting.
3.3. Safety. There were no unanticipated adverse device
effects (UADEs), and no deaths were attributed to the inves-
tigational device. In the ITT cohort, 4 patients experienced
6 serious adverse events (SAE’s) deemed potentially (3)
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Table 4: Comparison to recent publications.
First author Enrollment Number ofcenters
Number of
patients
Metal stent
type and
covering∗
Recurrent
biliary
obstruction rate
Stent
patency at
6 months
Migration
rate
Cholecystitis
rate
Pancreatitis
rate
Costamagna
[7] 5 months 6 66 PCWallFlex 6% (4) 94% 3% (2) 5% (3) 2% (1)
Isayama [8] 60 months 4 138
PC
Wallstent 21% (29) — 17% (24) 7% (9) 4% (5)
11 months 20 141 PCWallFlex 26% (36) 78% 8% (11) 10% (14) 6% (8)
Kullman [9] 34 months 10 200
UC
Nitinella 23% (45) 78% 0% (0) 1% (2) 2% (4)
200 PC Nitinella 24% (47) 74% 3% (6) 1% (2) 3/200
Petersen 6 months 10 55 FCWallFlex 2% (1) 91% 2% (1) 4% (2) 2% (1)
Song [10] 19 months 1 24
Paclitaxel
covered
SEMS
21% (5) — 0% (0) 0% (0) 4% (1)
25 FC SEMS 32% (8) — 16% (4) 0% (0) 0% (0)
Talreja [11] 41 months 6 260 FCWallFlex 3% (8) 63% 2% (4) 1% (2) 2% (4)
Telford [12] 68 months 4
61 UCWallstent 18% (11) 90% 0% (0) 5% (3) 2% (1)
68 PCWallstent 29% (20) 87% 12% (8) 4% (3) 0% (0)
Tringali [13] 30 months Unknown(multicenter) 70 PC ComVi 30% (21) 70% 4% (3) 1% (1) 0% (0)
∗FC: fully covered; PC: partially covered; UC: uncovered.
or probably (3) related to the study device. Cholecystitis
occurred in 2 patients, 1 of whom also experienced gallblad-
der perforation. In this patient, purulent bile and gallstones
were noted at the time of prior plastic stent removal during
the index procedure. In both patients who experienced
cholecystitis the stents were placed across the cystic duct;
however, it is unknownwhether therewas tumor involvement
at that level. Both events resolved with antibiotics and
percutaneous gallbladder drain placement. The prevalence
of intact gallbladders among treated patients was not sys-
tematically documented; hence the rate of acute cholecystitis
among thosewith intact gallbladders is unknown. Post-ERCP
pancreatitis occurred in one patient who later also developed
self-limited RUQ pain. One patient experienced severe, self-
limited postprocedural nausea. The SAE of cholangitis/stent
occlusion at day 142 noted in the effectiveness section was
reported by the investigator as related to progression of
underlying disease rather than the stent. The stent migration
reported in the effectiveness section was not associated with
an adverse event as it did not lead to patient symptoms.
Six additional patients experienced a total of 7 SAEs
reported as probably or possibly related to the ERCP itself,
including one case of respiratory compromise during proce-
dural sedation, culminating in death 8 days later from result-
ing sequelae and underlying pancreatic cancer, and one case
each of post-ERCP pancreatitis and of postsphincterotomy
bleeding, both of which resolvedwithout sequelae. Individual
cases of fever, abdominal pain, and nausea thatmay have been
procedure related resolved without sequelae.
4. Discussion
Studies of endoscopic palliation for malignant inoperable
obstructive jaundice have demonstrated the therapeutic
advantage and cost effectiveness of self-expanding metal
stents compared to surgical bypass or placement of plastic
stents [2, 14, 15]. The efficacy of bare metal stents is limited
by the propensity for tumor ingrowth [16]. Similarly, partially
covered SEMSs remain prone to obstruction by ingrowth and
overgrowth of tumor and by hyperplastic tissue response at
the short bare segment at the upper end. Thus, the potential
benefit of the central covering is offset by the persistent
risk of occlusion at the uncovered ends [12, 17–19]. Fully
covered designs without sharp wire ends may preclude these
complications and thereby yield prolonged freedom from
stent occlusion. In this series, only one patient experienced
recurrent biliary obstruction, after 142 days.
Recurrent biliary obstruction caused by migration or
stent occlusion remains the most important issue. It is still
unproven whether CSEMS will be a better solution than
uncovered SEMS as evidenced by 2 recently published ran-
domized studies, [9, 12]; however, a recent meta-analysis [20]
showed significantly prolonged stent patency and stent sur-
vival for covered stents. Data from this series and Costa-
magna et al. [7] suggest that the covered WallFlex stent
design may lead to a lower recurrent biliary obstruction rate
compared to older designs (Table 4). Despite the full length
covering on theWallFlex stent used in the present series, only
one stent migrated, and this was asymptomatic in a patient
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with presumed stricture improvement following radiation
therapy. Stent replacement was not required.
This study of a new fully covered SEMS demonstrates
successful endoscopic palliation of unresectable malignant
distal biliary obstruction in 98% of patients, suggesting that
the goals of various stent design features were mostly met. As
in most studies of biliary SEMS, technical placement success
was almost universal. One stent failed to deploy adequately
and was immediately replaced by a commercially available
stent. Twopatients’ stentswere incorrectly sized and therefore
removed and replaced with different lengths. The narrow
mesh design of the Wallflex stent foreshortens during place-
ment and requires some attention to placement, compared to
the wider mesh nonforeshortening laser cut designs.
For practical purposes bare SEMSs are not removable fol-
lowing the procedure at which they were inserted. Although
there are descriptions of successful removal of uncovered
biliary stents, it is technically difficult to perform and not
predictable [21]. The partially and fully covered metal stents
do not carry labeling for removability in the USA; however,
they have been employed “off-label” for limited durations in
various nonmalignant conditions such as benign strictures
[22, 23] and intractable bile leaks [23, 24]. The partially
covered versions are still prone to proximal ingrowth and
potentially difficult removal [25, 26]. This limits their use
in benign applications, and some authors consider them
inappropriate for use in patients with a life expectancy
greater than 24 months [27]. In this study, we used a fully
covered stent that is retained by collapsible flares at the ends,
which make repositioning or immediate removal relatively
atraumatic and highly predictable. In the porcine model this
stent design was removed shortly after placement from all six
animals without difficulty [28]. Similarly, in this study three
stents were removed immediately without difficulty from two
patients. If this ease of removal is confirmed in subsequent
studies with longer indwell periods, this stent may alter the
paradigm for palliation of indeterminate biliary strictures
that are presumed to bemalignant but are still undefined [21].
As reported by Siddiqui et al., [29] fully covered CSEMS can
nowbe used as an initial intervention to relievemalignant bil-
iary obstruction, even in patients whose surgical resectability
status is uncertain; however, the use of the stent in such man-
ner would be considered “off-label” in the USA. Placement
prior to or at the time of biopsy and prior to assessment of
operability could then proceed without concern about the
risk for permanence in potentially benign lesions or in lesions
likely to resolve with medical therapy, such as strictures
related to lymphoma or IgG4-related disease. Of note in this
series, three patients were originally considered inoperable
but later went on to surgery and en bloc stent removal.
This study is limited by the lack of a comparison group.
Also, 17 patients in this series died of their underlying disease
within three months, limiting assessment of the duration
of freedom from stent occlusion. Nevertheless, insertion
success, duration of adequate clinical palliation, and compli-
cations were all superior or comparable to most published
data on self-expanding biliary stents. Comparative trials of
this fully covered stent versus noncovered or partially covered
metal stents for extrahepatic malignant applications and
versus multiple plastic stents for benign lesions are needed.
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